Artivion (AORT)
(Delayed Data from NYSE)
$26.41 USD
+0.21 (0.80%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $26.40 -0.01 (-0.04%) 5:04 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.41 USD
+0.21 (0.80%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $26.40 -0.01 (-0.04%) 5:04 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Zacks News
Does Artivion (AORT) Have the Potential to Rally 52.78% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 52.8% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Artivion (AORT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 500% and 5.69%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Artivion (AORT) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 166.67% and 2.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Sight Sciences, Inc. (SGHT): Can Its 5.6% Jump Turn into More Strength?
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Artivion (AORT) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 158.82% and 1.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Artivion (AORT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Artivion (AORT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Think Artivion (AORT) Could Surge 79%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 79.4% upside potential for Artivion (AORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict a 173% Upside in Artivion (AORT): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 173.4% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Artivion (AORT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 54.55% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of 0% and 4.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
SARTORIUS (SARTF) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
SARTORIUS (SARTF) delivered earnings and revenue surprises of 7.39% and 7.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
KORU Medical Systems Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 0% and 4.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
What Makes Artivion (AORT) a New Buy Stock
by Zacks Equity Research
Artivion (AORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Artivion (AORT) Soars 10.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Artivion (AORT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Sensus Healthcare, Inc. (SRTS) Moves 7.3% Higher: Will This Strength Last?
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Strength Seen in Masimo (MASI): Can Its 7.7% Jump Turn into More Strength?
by Zacks Equity Research
Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Artivion (AORT) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 100% and 1.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Artivion (AORT) Q4 Earnings Expected to Decline
by Zacks Equity Research
Artivion (AORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.